Oct 4, 2021 | Anti-METH antibody, IXT-m200, General News, Grants
Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE ROCK, AR, USA, October 4, 2021 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the award of additional...
Sep 21, 2021 | Anti-METH antibody, IXT-m200, General News
LITTLE ROCK, AR, USA, September 20, 2021 – InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in Meth-OD, a Phase 2 study of the first-in-class anti-methamphetamine antibody IXT-m200 in...
Apr 19, 2021 | Anti-METH antibody, IXT-m200, General News
IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...
Oct 5, 2020 | Anti-METH antibody, IXT-m200, General News, Grants
“Meth-OD” trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical...
Jan 10, 2020 | General News, METH in the news
The misuse of methamphetamine, a highly addictive stimulant remains an extremely serious problem in the United States. Overdose deaths from meth are on the rise, caused in part by dealers who mix it with dangerous synthetic opioid fentanyl. Source: Overview | National...
Dec 20, 2019 | General News, METH in the news
Source: A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times
Recent Comments